Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation -Del ex9-12.

Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13-17% of ovarian cancers are due to heritable mutations in and . The (-Del ex9-12) Mexican founder mutation is responsible for 28-35% of the cases with ovarian cancer. The aim was to describe the PFS of OC patients treated with olaparib, emphasizing patients carrying the Mexican founder mutation (-Del ex9-12). In this observational study, of 107 patients with m, 35 patients were treated with olaparib from November 2016 to May 2021 at the Ovarian Cancer Program (COE) of Mexico; patient information was extracted from electronic medical records. Of 311 patients, 107 (34.4%) were with m; 71.9% (77/107) were with , of which 27.3% (21/77) were with -Del ex9-12, and 28.1% (30/107) were with mutations. Only 35 patients received olaparib treatment, and the median follow-up was 12.87 months. The PFS of -Del ex9-12 was NR (non-reach); however, 73% of the patients received the treatment at 36 vs. 11.59 months (95% CI; 10.43-12.75) in patients with other m ( = 0.008). Almost 50% of patients required dose reduction due to toxicity; the most frequent adverse events were hematological in 76.5% and gastrointestinal in 4%. Mexican OC -Del ex9-12 patients treated with olaparib had a significant increase in PFS regardless of the line of treatment compared to other mutations in .